Target

ARID1A

AT-rich interactive domain-containing protein 1A

4open trials
11trials in total
39publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
ARID1A Stimulates Notch-TLL1 Signaling to Induce Cancer-Associated Fibroblast Activation and Intrahepatic Cholangiocarcinoma Development.
15 Oct 2026· Cancer research· PUBMED
Trial
TR115 in ARID1A-Mutated Advanced Solid Tumors
20 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Preprint
Tumor context determines ARID1A effects on gastric cancer immunity.
20 Aug 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
ARID1A regulates colorectal cancer metastasis through the AKT/mTOR/p70S6K pathway.
24 Jul 2026· Translational oncology· PUBMED
Publication
Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer.
21 Jul 2026· Cancer immunology, immunotherapy : CII· PUBMED
Publication
Prognostic Role of TP53 and ARID1A Mutations in Alcohol-Consuming Patients With Uterine Endometrioid Carcinoma.
13 Jul 2026· Applied immunohistochemistry & molecular morphology : AIMM· PUBMED
Publication
From regeneration to tumorigenesis: ARID1A as an epigenetic guardian of gastric identity.
8 Jul 2026· Developmental cell· PUBMED
Publication
ARID1A terminates gastric regeneration to prevent cancer.
30 Jun 2026· Developmental cell· PUBMED
Publication
Biallelic ARID1A Alterations : A Promising Novel Biomarker for Risk Stratification and Management in Pediatric Malignant Hepatocellular Tumors.
16 Jun 2026· The American journal of surgical pathology· PUBMED
Publication
ARID1A-Retained and SMARCA4-Aberrant Gastric Solid-Type Poorly Differentiated Adenocarcinoma and Prognosis: A Retrospective Cohort Study.
12 Jun 2026· International journal of surgical pathology· PUBMED
Publication
[ARID1A-deficient endometrial carcinoma: a clinicopathological analysis of five cases].
8 Jun 2026· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publication
ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability.
3 Jun 2026· Molecular cancer research : MCR· PUBMED
Publication
ARID1A loss drives gastric signet ring cell carcinoma by regulating mucin production and secretion.
2 Jun 2026· Nature communications· PUBMED
Publication
Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.
26 May 2026· Nature communications· PUBMED
Publication
ARID1A loss drives osimertinib resistance by epigenetically suppressing PTEN and activating the Akt pathway in lung cancer.
20 May 2026· Biochemical and biophysical research communications· PUBMED
Publication
Efficacy of immune checkpoint inhibitor plus chemotherapy in ARID1A-mutated advanced gastric cancer.
15 May 2026· Therapeutic advances in gastroenterology· PUBMED
Publication
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer.
15 May 2026· Cancer research· PUBMED
Publication
ARID1A mutation is associated with an immunosuppressive microenvironment and poor prognosis in hepatocellular carcinoma: An integrated bioinformatics analysis.
12 May 2026· Immunobiology· PUBMED
Publication
ARID1A, β-Catenin and P53 Immunohistochemical Expression: Diagnostic Value in Endometrial Carcinoma and Premalignant Endometrial Lesions.
10 May 2026· Iranian journal of pathology· PUBMED
Publication
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
1 May 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report.
26 Apr 2026· Translational lung cancer research· PUBMED
Publication
ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma.
10 Apr 2026· Cell death & disease· PUBMED
Publication
Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer.
10 Apr 2026· Communications biology· PUBMED
Publication
ARID1A deficiency-driven reprogramming of polyamine metabolism promotes endometrial cancer malignancy and immune escape.
8 Apr 2026· Cell death & disease· PUBMED
Publication
The features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype: a retrospective study in a large Chinese cohort.
13 Mar 2026· Journal of cancer research and clinical oncology· PUBMED
Publication
Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation.
9 Mar 2026· Molecular cancer· PUBMED
Publication
MicroRNA-663a upregulation upon ARID1A depletion promotes the growth and migration of esophageal cancer cells by targeting FKBP8.
26 Feb 2026· Translational cancer research· PUBMED
Publication
Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms.
18 Feb 2026· Molecular systems biology· PUBMED
Publication
ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition.
11 Feb 2026· International journal of biological sciences· PUBMED
Publication
Targeting miR-4653-3p/SLC25A51/SIRT3 axis to induce synthetic lethality in ARID1A-deficient colorectal cancer via blockade of DNA repair.
4 Feb 2026· Journal of translational medicine· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error